Table 3. Biological parameters during HU... | American Society of Hematology

Table 3.

Biological parameters during HU treatment: changes from T0 (ΔHU-T0) and values in patients with or without α thalassemia and in the 3 major homozygous β haplotypes

	α Thalassemia						β Haplotypes
	ΔHU-T0			With HU			ΔHU-T0	With HU	ΔHU-T0	With HU	ΔHU-T0	With HU	ΔHU-T0	With HU
	Absent	Present	Abs vs present, P	Absent	Present	Absent vs present, P	CAR/CAR		BEN/BEN		SEN/SEN		CAR/CAR vs BEN/BEN, P
No. of patients	84	69	—	84	69	—	77		41		12		—	—
Leukocytes, ×10⁹/L	−5.3 ± 4.8	−5.7 ± 5.8	NS	8.9 ± 3.6	7.8 ± 4.2	NS	−5.8 ± 5.1	7.5 ± 3.4	−6.3 ± 5.6	8.7 ± 4.1	−1.9 ± 3.1	11.2 ± 4.2	NS	NS
Neutrophils, ×10⁹/L	−2.8 ± 6.3	−3.1 ± 3.9	NS	4.7 ± 4.7	3.7 ± 2.3	NS	−3.5 ± 3.7	3.4 ± 1.6	−3.0 ± 3.4	3.9 ± 2.8	−1.2 ± 3.3	6.2 ± 3.4	NS	NS
Platelets, ×10⁹/L	−43 ± 127	−88 ± 112	.023	344 ± 121	285 ± 119	.002	−51 ± 112	305 ± 118	−105 ± 137	319 ± 132	−5 ± 163	389 ± 161	.037	NS
Hb, g/dL	0.7 ± 1.2	0.7 ± 1.3	NS	8.7 ± 1.2	8.8 ± 1.2	NS	0.7 ± 1.2	8.5 ± 1.1	1.0 ± 1.3	9.2 ± 1.3	0.8 ± 0.8	8.9 ± 1.4	NS	.007
Reticulocytes, ×10⁹/L	−142 ± 122	−117 ± 101	NS	184 ± 90	158 ± 73	.048	−129 ± 96	162 ± 71	−144 ± 120	168 ± 82	−89 ± 109	210 ± 98	NS	NS
MCV, fL	16.1 ± 9.6	11.7 ± 8.0	.003	100.4 ± 12.1	86.1 ± 9.2	<.001	13.6 ± 9.9	91.5 ± 13.3	17.2 ± 9.1	99.3 ± 13.3	12.0 ± 4.3	91 ± 11.8	NS	.003
HbF, %	10.1 ± 6.8	8.1 ± 7.7	NS	18.7 ± 8.2	17.1 ± 8.1	NS	8.3 ± 7.4	16.6 ± 7.4	12.1 ± 8.4	21.2 ± 9.6	8.3 ± 7.7	19.1 ± 9.2	.026	.005
Bilirubin, mmol/L	−11.0 ± 29.1	−7.5 ± 22.1	NS	38.8 ± 28.6	32.9 ± 21.0	NS	−9.3 ± 25.8	37 ± 24	−14.7 ± 20.8	30 ± 31	−5.1 ± 27.3	39 ± 33	NS	NS
LDH, IU/L	−207 ± 340	−177 ± 256	NS	696 ± 669	575 ± 264	NS	−181 ± 280	604 ± 281	−298 ± 347	734 ± 929	−63 ± 101	520 ± 234	NS	NS

	α Thalassemia						β Haplotypes
	ΔHU-T0			With HU			ΔHU-T0	With HU	ΔHU-T0	With HU	ΔHU-T0	With HU	ΔHU-T0	With HU
	Absent	Present	Abs vs present, P	Absent	Present	Absent vs present, P	CAR/CAR		BEN/BEN		SEN/SEN		CAR/CAR vs BEN/BEN, P
No. of patients	84	69	—	84	69	—	77		41		12		—	—
Leukocytes, ×10⁹/L	−5.3 ± 4.8	−5.7 ± 5.8	NS	8.9 ± 3.6	7.8 ± 4.2	NS	−5.8 ± 5.1	7.5 ± 3.4	−6.3 ± 5.6	8.7 ± 4.1	−1.9 ± 3.1	11.2 ± 4.2	NS	NS
Neutrophils, ×10⁹/L	−2.8 ± 6.3	−3.1 ± 3.9	NS	4.7 ± 4.7	3.7 ± 2.3	NS	−3.5 ± 3.7	3.4 ± 1.6	−3.0 ± 3.4	3.9 ± 2.8	−1.2 ± 3.3	6.2 ± 3.4	NS	NS
Platelets, ×10⁹/L	−43 ± 127	−88 ± 112	.023	344 ± 121	285 ± 119	.002	−51 ± 112	305 ± 118	−105 ± 137	319 ± 132	−5 ± 163	389 ± 161	.037	NS
Hb, g/dL	0.7 ± 1.2	0.7 ± 1.3	NS	8.7 ± 1.2	8.8 ± 1.2	NS	0.7 ± 1.2	8.5 ± 1.1	1.0 ± 1.3	9.2 ± 1.3	0.8 ± 0.8	8.9 ± 1.4	NS	.007
Reticulocytes, ×10⁹/L	−142 ± 122	−117 ± 101	NS	184 ± 90	158 ± 73	.048	−129 ± 96	162 ± 71	−144 ± 120	168 ± 82	−89 ± 109	210 ± 98	NS	NS
MCV, fL	16.1 ± 9.6	11.7 ± 8.0	.003	100.4 ± 12.1	86.1 ± 9.2	<.001	13.6 ± 9.9	91.5 ± 13.3	17.2 ± 9.1	99.3 ± 13.3	12.0 ± 4.3	91 ± 11.8	NS	.003
HbF, %	10.1 ± 6.8	8.1 ± 7.7	NS	18.7 ± 8.2	17.1 ± 8.1	NS	8.3 ± 7.4	16.6 ± 7.4	12.1 ± 8.4	21.2 ± 9.6	8.3 ± 7.7	19.1 ± 9.2	.026	.005
Bilirubin, mmol/L	−11.0 ± 29.1	−7.5 ± 22.1	NS	38.8 ± 28.6	32.9 ± 21.0	NS	−9.3 ± 25.8	37 ± 24	−14.7 ± 20.8	30 ± 31	−5.1 ± 27.3	39 ± 33	NS	NS
LDH, IU/L	−207 ± 340	−177 ± 256	NS	696 ± 669	575 ± 264	NS	−181 ± 280	604 ± 281	−298 ± 347	734 ± 929	−63 ± 101	520 ± 234	NS	NS

Data are presented as mean ± SD unless indicated otherwise.

No significant difference was found in the dose of HU independent of α- or β-haplotype status.

View Large

This Feature Is Available To Subscribers Only